Notably, these findings closely resemble those in Figure S7B, where engineered Tnfsf9-expressing tumor cells in Il12+/+ mice showed a therapeutic benefit without rIL-12—likely because CD8 T cell priming and subsequent 4–1BB expression occurred during tumor engraftment. This evidence concerns the gene CD8A and neoplasm.